Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 6/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.39 |
| ▸ | GRK6 | P43250 | 3/20 | 0.37 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1365887 | 0.73 | NTRK1 (0.50) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL1365884 | 0.73 | NTRK1 (0.50) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL26614705 | 0.68 | HDAC6 (0.54) | EGFRNTRK1 | |
| SCHEMBL26614702 | 0.68 | HDAC6 (0.54) | EGFRNTRK1 | |
| SCHEMBL4509392 | 0.67 | GPR139 (0.44) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL4372820 | 0.66 | HTR7 (0.61) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL13676577 | 0.65 | HTR7 (0.37) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL13676629 | 0.65 | HTR7 (0.37) | HTR7ADRA1DADRA1AADRA1BHTR2C | |
| SCHEMBL3921915 | 0.65 | HTT (0.30) | — | |
| SCHEMBL27850423 | 0.65 | HTR7 (0.52) | HTR7ADRA1DADRA1AADRA1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049542-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-19 | — | — | EP | disclosed |
| US-7605160-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080058337-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058337-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | NTRK2, NTRK1, NTRK3 | HTR7 962/4885ADRA1D 2234/4885ADRA1A 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.